Media ReleasesBARD1 Life Sciences

View All BARD1 Life Sciences News

BARD1 Life Sciences $15m Placement to Accelerate Cancer Diagnostic Program

BARD1 completes $15 million placement with strong demand from new and existing institutional and sophisticated investors in Australia and Hong Kong

• Proceeds will be used primarily to fund development and commercialisation of the SubB2M tests for ovarian and breast cancer, and EXO-NET® products
• Existing shareholders will be offered the opportunity to participate in a Share Purchase Plan to raise up to a further $2 million on the same terms as the placement
• BARD1’s expected proforma net cash balance will be approximately $20.6 million post placement and SPP1

Melbourne, Australia, 23 July 2021: BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company) is pleased to announce that the Company has raised $15 million in a placement to sophisticated, institutional and professional investors showing strong support for the Company’s development and commercialisation programs focused on the early detection of cancer to improve patient outcomes.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.